Navidea Biopharmaceuticals Inc. announced it has entered into a distribution agreement for Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection in Taiwan with Global Medical Solutions Taiwan, Ltd. (GMST). The contract with GMST follows an agreement recently signed for Lymphoseek distribution in Canada, affording local access to that market as well. Navidea has also recently commenced shipment of Lymphoseek to select medical centers in the Middle East.

These market expansion activities build on the growth of Lymphoseek sales in the United States, which continue the positive trends recently reported at the Company's Analyst Science Day on December 5, 2013. The Companies will work together to address all needed Taiwanese FDA regulatory requirements and expect local approval in 2014-15. Prior to complete regulatory approval, in appropriate situations, the product will be made available in accordance with named-patient mechanisms. The agreement anticipates distribution of non-radioactive kits as well as unit-dose product which will be radiolabelled at the GMST commercial radiopharmacy, affording flexibility in meeting the needs of end-users in the Taiwanese market.